Another study examining brain tumors found similar results; the expression of E-cadherin was observed in 8/92 gliomas with weak staining intensity in the majority of the immunoreactive cases (7/8), while the expression of N-cadherin was identified in 81/92 cases, although the correlation between presence of both cadherin expression and WHO tumor grades (low-grade vs. high-grade) was not significant statistically [29]. Here, CDH17 is linked to central nervous system cancer.